The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Chemotherapy (CTX) treatment patterns for early-stage breast cancer (ESBC): Changing use of anthracyclines (A).
Katherine M. Serrurier
No relevant relationships to disclose
Jimmy Hwang
No relevant relationships to disclose
Joseph P. McGuire
No relevant relationships to disclose
Daphne Lichtensztajn
No relevant relationships to disclose
Ann C. Griffin
No relevant relationships to disclose
Scarlett Lin Gomez
No relevant relationships to disclose
Allison W. Kurian
No relevant relationships to disclose
Michelle E. Melisko
No relevant relationships to disclose
Hope S. Rugo
No relevant relationships to disclose